Review on Zika Virus

  • Posted on: 30 December 2017
  • By: admin

Pharma Admission


pharma admission




Magazine Home

January 2018 ARTICLE LIST >>

PharmaTutor (January - 2018)


ISSN: 2347 - 7881
(Volume 6, Issue 1)


Received On: 27/08/2017; Accepted On: 20/09/2017; Published On: 01/01/2018


Nayan Jain*, Ashutosh Biswas, Kratika Vivek Daniel
Mandsaur Institute of pharmacy,
Mandsaur , MP, India



Today the world has suffered to the Zika virus is a flavivirous related to yellow fever, dengue, West Nile and Japanese encephalis virus. Zika virus causes acute, serious illness which is often fatal if it is not treated. Its name comes from the Zika forest of Uganda. Zika is a mosquito born disease. Zika virus disease is caused by a virus transmitted primarily by Aedes mosquitoes. People with Zika virus disease can have symptoms including mild fever, skin rash, conjunctivitis, muscle and joint pain, malaise or headache. These symptoms normally last for 2-7 days. There is scientific consensus that Zika virus is a cause of microcephaly and Guillain-Barré syndrome. Links to other neurological complications are also being investigated. Neither an effective treatment nor a vaccine is available for Zika virus; therefore, the public health response primarily focuses on preventing infection, particularly in pregnant women. This article also covers from where the zika was firstly introduced or its history, its transmissions, causes, diagnosis, treatment and some current affairs..



How to cite this article: Jain N, Biswas A, Daniel KV; Review on Zika Virus; PharmaTutor; 2018; 6(1); 30-37;